이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Medivir 관리

관리 기준 확인 1/4

Medivir's CEO는 Jens Lindberg, Jan2022 에 임명되었습니다 의 임기는 2.42 년입니다. 총 연간 보상은 SEK 7.82M, 32.8% 로 구성됩니다. 32.8% 급여 및 67.2% 보너스(회사 주식 및 옵션 포함). 는 SEK 494.31K 가치에 해당하는 회사 주식의 0.15% 직접 소유합니다. 494.31K. 경영진과 이사회의 평균 재임 기간은 각각 3.6 년과 0.8 년입니다.

주요 정보

Jens Lindberg

최고 경영자

SEK 7.8m

총 보상

CEO 급여 비율	32.8%
CEO 임기	2.5yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	3.7yrs
이사회 평균 재임 기간	less than a year

최근 관리 업데이트

Recent updates

CEO 보상 분석

Jens Lindberg 의 보수는 Medivir 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-SEK 97m
Dec 31 2023	SEK 8m	SEK 3m	-SEK 89m
Sep 30 2023	n/a	n/a	-SEK 87m
Jun 30 2023	n/a	n/a	-SEK 78m
Mar 31 2023	n/a	n/a	-SEK 75m
Dec 31 2022	SEK 3m	SEK 2m	-SEK 89m

보상 대 시장: Jens 의 총 보상 ($USD 749.68K )은 Swedish 시장( $USD 257.75K ).

보상과 수익: 회사가 수익성이 없는 동안 Jens 의 보상이 증가했습니다.

CEO

Jens Lindberg (53 yo)

2.5yrs

테뉴어

SEK 7,824,000

보상

Mr. Jens Lindberg serves as Board Member of BrainCool AB (publ) from June 26, 2024. He serves as Chief Executive Officer at Medivir AB (publ) since January 24, 2022. He served as Acting Chief Executive Off...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jens Lindberg	Chief Executive Officer	2.5yrs	SEK 7.82m	0.15% SEK 482.6k
Magnus Christensen	Chief Financial Officer	4.9yrs	SEK 2.66m	0.081% SEK 263.0k
Fredrik Öberg	Chief Scientific Officer	4.8yrs	데이터 없음	0.11% SEK 358.1k
Pia Baumann	Chief Medical Officer	1.4yrs	데이터 없음	0.086% SEK 277.5k
Karin Tunblad	Senior Principal Scientist & MIV-818 Project Leader	no data	데이터 없음	데이터 없음

3.7yrs

평균 재임 기간

55.5yo

평균 연령

경험이 풍부한 관리: MVIR 의 관리팀은 경험 ( 3.6 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Lennart Hansson	Independent Director	6.2yrs	SEK 260.00k	0.036% SEK 115.6k
Uli Hacksell	Chairman of the Board	6.2yrs	SEK 690.00k	0.89% SEK 2.9m
Yilmaz Mahshid	Director	3.2yrs	SEK 260.00k	0.045% SEK 144.5k
Jeong-Woo Heo	Member of Scientific Advisory Council	less than a year	데이터 없음	데이터 없음
Bengt Westermark	Independent Director	7.2yrs	SEK 260.00k	0.029% SEK 92.5k
Jeffrey Evans	Member of Scientific Advisory Council	less than a year	데이터 없음	데이터 없음
Richard Finn	Member of Scientific Advisory Council	less than a year	데이터 없음	데이터 없음
Maria Reig	Member of Scientific Advisory Council	less than a year	데이터 없음	데이터 없음
Arndt Vogel	Member of Scientific Advisory Council	less than a year	데이터 없음	데이터 없음
Anna Torner	Director	less than a year	데이터 없음	데이터 없음
Angelica Loskog	Director	less than a year	데이터 없음	데이터 없음

0.9yrs

평균 재임 기간

74yo

평균 연령

경험이 풍부한 이사회: MVIR 의 이사회는 경험(평균 재직 기간 0.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Medivir 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Chief Executive Officer recently bought kr176k worth of stock

Medivir Aktiebolag (publ) Approves Board Appointments

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

High number of new and inexperienced directors

Independent Chairman of the Board recently bought kr374k worth of stock

Recent updates

New major risk - Financial position

Consensus EPS estimates fall by 45%

Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide (Fostrox) + Lenvima® in Advanced Hepatocellular Carcinoma (HCC)

Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility

Chief Executive Officer recently bought kr176k worth of stock

Medivir Aktiebolag (publ) Approves Board Appointments

Consensus revenue estimates increase by 21%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates fall by 90%

Price target decreased by 8.2% to kr22.49

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Medivir AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

New major risk - Shareholder dilution

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 20.000001 million.

Medivir Presents the First Clinical Data with Fostrox + Lenvima At the Asco GI Scientific Congress

Medivir AB Announces Further Improved Clinical Benefit with Fostrox + Lenvima as Data from the Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancer

Price target decreased by 16% to kr23.39

Medivir AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 128.961315 million.

Medivir AB Announces Data from Ongoing Phase 1B/2A Study in Advanced Hepatocellular Cancers

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB Announces Updated Formulation of Fostrox Critical to Support Planned Study with Accelerated Approval Intent in Second Line HCC

Medivir AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 147.979713 million.

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Consensus revenue estimates fall by 78%

New major risk - Financial position

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Medivir AB (publ) to Report First Half, 2024 Results on Aug 22, 2024

Medivir AB (publ) to Report Q1, 2024 Results on Apr 30, 2024

New minor risk - Share price stability

Medivir AB (publ), Annual General Meeting, May 07, 2024

Medivir AB (Publ) Announces Resignation of Anette Lindqvist as Director

Medivir AB Announces All Patients in the Ongoing Phase 2A Study in Advanced Hepatocellular Car Car Car Carcinoma Has Now Dosed At Least Two Treatment Cycle

Medivir AB Reports Promising Interim Data, Including A First Complete Response in Phase 1B/2A Hcc Study with Fostrox in Combination with Lenvima

High number of new and inexperienced directors

Consensus revenue estimates increase by 47%, EPS downgraded

Independent Chairman of the Board recently bought kr374k worth of stock

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Medivir AB Announces 15th Patient with Advanced Liver Cancer Has Been Included in the Ongoing Phase 2A Study

Medivir AB Announces Formation of A Scientific Advisory Council

Is Medivir (STO:MVIR) In A Good Position To Invest In Growth?

Medivir AB Announces Patent Application for Fostrox Approval in China

Medivir AB Completes the Dose Escalation Part (Phase 1B) of the 1B/2A Study in Hcc and Focus on the Combination of Fostrox and Lenvima

Chief Executive Officer recently bought kr209k worth of stock

Price target increased by 14% to kr28.08

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 16%, revenue upgraded

Price target increased by 13% to kr27.96

Forecast to breakeven in 2024

Less than half of directors are independent

Medivir Completes A Successful Pre-IND Meeting with the FDA

Medivir AB (Publ) Appoints Pia Baumann as New Chief Medical Officer

Medivir AB (Publ) Appoints Nomination Committee

Medivir AB (publ) to Report Q2, 2023 Results on Aug 18, 2023

Medivir AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Medivir Aktiebolag (Publ) Announces Board Changes

Medivir AB (publ) to Report Fiscal Year 2021 Final Results on Apr 05, 2022

Medivir AB (Publ) Announces Phase II Study of Miv-711 for Osteoarthritis Shows Statistically Significant Reduction in Oa Pain

Medivir AB (publ) Announces Abstract for MIV-818 phase 1b monotherapy for ESMO Congress published

Medivir AB Announces Positive Data from the Remetinostat Phase II Study in Basal Cell Carcinoma Published in Clinical Cancer Research

Medivir Announces the Design of its Upcoming MIV-818 Combination Study

Medivir AB Announces Positive Results from Investigator-Initiated Phase II Clinical Study of Remetinostat in Patients with Squamous Cell Carcinoma

Medivir AB (publ), Annual General Meeting, May 05, 2021

Medivir AB Announces Delisting of Paid Subscription Shares

Medivir AB Enters into Licensing Agreement with Ubiquigent Limited for Preclinical Program USP7

New 90-day low: kr8.00

IGM Biosciences, Inc. Enters into Exclusive Licensing Agreement with Medivir for Birinapant

Is Medivir (STO:MVIR B) In A Good Position To Deliver On Growth Plans?

New 90-day low: kr8.25